查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423650

到 2030 年停經後骨質疏鬆症治療市場預測：按治療類型、給藥途徑、給藥系統、患者人口統計、分銷管道和地區進行全球分析

Postmenopausal Osteoporosis Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type, By Route of Administrations, By Drug Delivery System, Patient Demographics, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球停經後骨質疏鬆症治療市場規模將達到 81 億美元，預計 2030 年將達到 126 億美元，預測期內複合年成長率為 6.6%。

停經後骨質疏鬆症治療包括藥物治療和生活方式改變，以減輕停經後婦女的骨質流失。常見的治療方法包括雙磷酸鹽、荷爾蒙療法和單株抗體，旨在增強骨骼並降低骨折風險。這些治療方法可以幫助維持骨骼密度、緩解症狀並改善整體骨骼健康。

根據世界衛生組織（WHO）2021年10月的報告，60歲及以上的人口預計將從2020年的10億增加到2030年的14億和2050年的21億。根據國際更年期協會（IMS）公佈的資料，預計2021年將有超過2億女性受到骨質疏鬆症的影響，其中三分之一的50歲以上女性會因骨質疏鬆症而發生骨折。 。

世界老化人口增加

隨著越來越多的人在閉經後患有骨質疏鬆症，骨質疏鬆症（一種以骨骼密度下降和骨折風險增加為特徵的疾病）的盛行率也在增加。這些人口變化正在增加對有效治療方案的需求，並推動研究和開發工作，以滿足停經後婦女的獨特需求。製藥公司越來越注重治療方法，以幫助解決老齡化人口對骨質疏鬆症相關併發症的脆弱性。隨著醫療保健系統努力滿足不斷變化的需求，它正在推動市場成長。

治療費用高

與骨質疏鬆症藥物和治療方法相關的經濟負擔對廣泛提供和負擔得起的治療提出了挑戰，特別是對於醫療資源有限和保險不足地區的患者而言。骨質疏鬆症的治療費用通常不僅包括藥物費用，還包括診斷程序、監測測試和潛在副作用的管理，進一步加重了患者的經濟負擔。由於骨質疏鬆症是一種需要長期管理的慢性疾病，累積的財務影響可能會阻礙人們尋求和繼續治療。

人們越來越認知到骨骼健康的重要性

人們對骨質疏鬆症風險和後果的認知不斷提高，增加了對預防和治療性介入的需求。公共教育宣傳活動和舉措在鼓勵個人優先考慮骨骼健康、及時檢查和接受適當治療方面發揮著至關重要的作用。這種認知的提升不僅有助於早期診斷，還能鼓勵骨質疏鬆症藥物的採用，鼓勵患者更好地照顧自己的骨骼健康，預防停經後骨質疏鬆症相關的併發症，創造積極的市場環境。

副作用和安全問題

雖然各種藥物干預措施旨在解決停經後婦女的骨骼健康問題，但潛在的副作用可能導致患者依從性降低和治療停止。胃腸道紊亂、肌肉骨骼疼痛等常見副作用，以及某些情況下非典型骨折和下顎骨壞死等嚴重併發症，引起了患者和醫療保健提供者的擔憂。這些安全問題不僅影響受影響人群的生活品質，也損害了市場的信譽和可信度。

COVID-19 的影響：

COVID-19 的疫情對市場產生了重大影響。封鎖、醫療服務中斷以及對抗病毒的資源轉移給患者診斷和治療帶來了挑戰。醫療預約的延誤和患者就診的減少正在影響骨質疏鬆症的管理。此外，供應鏈中斷也影響了藥品的供應。然而，大流行加速了遠端醫療和數位醫療解決方案的採用，為患者照護提供了替代方案。對整體醫療保健彈性和預防措施重要性的關注可能會影響停經後骨質疏鬆症管理的疫情後策略。

荷爾蒙替代療法預計將成為預測期內最大的市場

荷爾蒙替代療法領域預計將出現良好的成長。在停經後女性中，雌激素水平下降會增加骨吸收並增加骨質疏鬆症的風險。荷爾蒙替代療法透過施用雌激素（有時還施用黃體素）來幫助維持骨骼密度並防止骨折，從而減少這些影響。儘管已證明有效，但由於相關風險（包括心血管問題），荷爾蒙替代療法的使用仍需經過仔細評估。正在進行的研究重點是最佳化 HRT通訊協定，以最大限度地提高療效，同時最大限度地減少停經後骨質疏鬆症管理的潛在缺點。

預計醫院藥房行業在預測期內的複合年成長率最高。

預計醫院藥房業務在預測期內將以最快的複合年成長率成長。醫院藥房確保處方藥物的供應，提供病患教育，並促進醫療保健專業人員和接受停經後骨質疏鬆症治療的患者之間的無縫合作。醫院藥房透過藥物管理方面的專業知識促進治療醫囑遵從性，並為患者提供獲取所需藥物（包括新興和創新治療方法）的中心樞紐。這種重要作用凸顯了其在支持有效的醫療保健提供和促進停經後骨質疏鬆症治療取得良好結果方面的重要性。

比最大的地區

預計北美市場在預測期內將繼續佔據大部分市場。該地區停經後骨質疏鬆症盛行率很高，對有效治療方法的需求很高。技術進步、知名製藥公司和有利的報銷政策正在促進市場成長。此外，該地區正在進行的研究計劃和臨床試驗重點關注創新治療方法，將北美定位為停經後骨質疏鬆症新先進治療方法開發和商業化的領先中心。

複合年成長率最高的地區：

在健康意識不斷提高的推動下，預計亞太地區在預測期內將呈現最高的複合年成長率。人口老化和骨質疏鬆症的高盛行率，特別是在日本和中國等國家，增加了對有效治療方法的需求。醫療保健意識的提高、醫療設施的改善以及政府解決女性健康問題的舉措正在進一步推動市場擴張。此外，製藥公司和醫療機構之間的合作，加上治療方法的進步，正在推動技術創新，改善亞太地區停經後骨質疏鬆症治療的整體格局。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球停經後骨質疏鬆症治療市場：依治療類型

  • 雙磷酸鹽
  • 荷爾蒙替代療法（HRT）
  • 選擇性雌激素受體調節劑 (SERM)
  • 單株抗體
  • 鈣和維生素 D補充品
  • 合成代謝劑
  • 其他治療類型

第6章全球停經後骨質疏鬆症治療市場：依給藥途徑

  • 口服
  • 胃腸外的
    • 靜脈注射(IV)
    • 肌肉注射
    • 皮下的
  • 經皮的
  • 鼻腔

第7章全球停經後骨質疏鬆症治療市場：依給藥系統分類

  • 常規配方
  • 長效製劑

第8章全球停經後骨質疏鬆症治療市場：病患分層

  • 停經後婦女
  • 老年人口

第9章全球停經後骨質疏鬆症治療市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章全球停經後骨質疏鬆症治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • AbbVie Company（Allergan Pharmaceuticals International Ltd.）
  • Sun Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • BiologicsMD
  • Chugai Pharma China Co., Ltd.（Roche）
  • Clonz Biotech
  • Proctor & Gamble Co.
  • Eli Lilly and Company
  • Enteris BioPharma
  • Ligand Pharmaceuticals Incorporated.
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp.（Merck & Co., Inc.）
  • Mylan Inc.（Viatris）
  • Oncobiologics, Inc.
  • Novartis International AG
Product Code: SMRC24884

According to Stratistics MRC, the Global Postmenopausal Osteoporosis Treatment Market is accounted for $8.1 billion in 2023 and is expected to reach $12.6 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Postmenopausal osteoporosis treatment involves medications and lifestyle modifications to mitigate bone loss in women after menopause. Common treatments include bisphosphonates, hormone therapy, and monoclonal antibodies, which aim to strengthen bones and reduce fracture risk. These treatments help maintain bone density, alleviate symptoms and enhance overall bone health.

According to the World Health Organization's October 2021 report, the population of people of age 60 years and more is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture.

Market Dynamics:

Driver:

The increasing global aging population

With a rising number of individuals entering the postmenopausal phase, there is a subsequent increase in the prevalence of osteoporosis, a condition characterized by reduced bone density and increased fracture risk. This demographic shift creates a growing demand for effective treatment options to address the specific needs of postmenopausal women, fostering research and development initiatives. Pharmaceutical companies are increasingly focusing on developing therapies tailored to this demographic, ranging from innovative drugs to targeted interventions, driving market growth as healthcare systems strive to meet the evolving needs of an aging population susceptible to osteoporosis-related complications.

Restraint:

High treatment costs

The financial burden associated with osteoporosis medications and therapies poses challenges to widespread accessibility and affordability, particularly for patients in regions with limited healthcare resources or inadequate insurance coverage. The cost of osteoporosis treatment often includes not only medication expenses but also diagnostic procedures, monitoring tests, and potential side-effect management, further exacerbating the economic burden on patients. As osteoporosis is a chronic condition requiring long-term management, the cumulative financial impact can dissuade individuals from seeking or continuing treatment.

Opportunity:

Growing awareness regarding the importance of bone health

As awareness grows regarding the risks and consequences of osteoporosis, there is a heightened demand for preventive and therapeutic interventions. Public education campaigns and healthcare initiatives play a pivotal role in encouraging individuals to prioritize bone health, undergo timely screenings, and seek appropriate treatment. This heightened awareness not only fosters early diagnosis but also propels the adoption of osteoporosis treatments, creating a positive market environment where patients are more proactive in managing their bone health and preventing complications associated with postmenopausal osteoporosis.

Threat:

Adverse effects and safety issues

While various pharmaceutical interventions aim to address bone health in postmenopausal women, the potential for adverse reactions may lead to decreased patient compliance and treatment discontinuation. Common side effects such as gastrointestinal disturbances, musculoskeletal pain, and, in some cases, severe complications like atypical fractures or osteonecrosis of the jaw raise concerns among both patients and healthcare providers. These safety issues not only impact the quality of life for affected individuals but also undermine the market's credibility and trust.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the market. Lockdowns, disrupted healthcare services, and diverted resources to combat the virus have led to challenges in patient diagnosis and treatment accessibility. Delayed medical appointments and reduced patient visits have affected osteoporosis management. Additionally, supply chain disruptions have impacted drug availability. However, the pandemic has accelerated the adoption of telemedicine and digital health solutions, offering alternative avenues for patient care. The focus on overall healthcare resilience and the importance of preventive measures may influence post-pandemic strategies in managing postmenopausal osteoporosis.

The hormone replacement therapy is expected to be the largest during the forecast period

The hormone replacement therapy segment is expected to have a lucrative growth. In postmenopausal women, reduced estrogen levels result in increased bone resorption, elevating the risk of osteoporosis. HRT involves the administration of estrogen and sometimes progestin to mitigate these effects, promoting bone density maintenance and fracture prevention. Despite proven efficacy, HRT usage is carefully evaluated due to associated risks, such as cardiovascular concerns. Ongoing research focuses on optimizing HRT protocols to maximize benefits while minimizing potential drawbacks in postmenopausal osteoporosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period. They ensure the availability of prescribed treatments, provide patient education, and facilitate seamless coordination between healthcare professionals and individuals undergoing postmenopausal osteoporosis treatment. Hospital pharmacies contribute to treatment adherence through their expertise in medication management, offering a centralized hub for patients to obtain necessary medications, including emerging and innovative therapies. This integral role underscores their significance in supporting effective healthcare delivery and promoting positive outcomes in the management of postmenopausal osteoporosis.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market driven by a substantial aging population and advanced healthcare infrastructure. The region benefits from a high prevalence of postmenopausal osteoporosis, necessitating a robust demand for effective treatments. Technological advancements, well-established pharmaceutical companies, and favorable reimbursement policies contribute to the market's growth. Moreover, ongoing research initiatives and clinical trials in the region focus on innovative therapies, positioning North America as a key hub for the development and commercialization of new and advanced treatments for postmenopausal osteoporosis.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, driven by a growing health-conscious population. The increasing aging population, particularly in countries like Japan and China, contributes to a higher prevalence of osteoporosis, driving the demand for effective treatments. Rising healthcare awareness, improving access to medical facilities, and government initiatives to address women's health issues further propel market expansion. Additionally, collaborations between pharmaceutical companies and healthcare organizations, coupled with advancements in treatment options, are fostering innovation and enhancing the overall landscape for postmenopausal osteoporosis treatment in the Asia Pacific region.

Key players in the market

Some of the key players in Postmenopausal Osteoporosis Treatment market include AbbVie Company (Allergan Pharmaceuticals International Ltd.), Sun Pharmaceutical Industries Ltd., Amgen Inc., BiologicsMD, Chugai Pharma China Co., Ltd. (Roche), Clonz Biotech, Proctor & Gamble Co., Eli Lilly and Company, Enteris BioPharma, Ligand Pharmaceuticals Incorporated., Pfizer Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Mylan Inc. (Viatris), Oncobiologics, Inc. and Novartis International AG.

Key Developments:

In February 2023, Sandoz received Biologics License Application (BLA) from US Food and Drug Administration (FDA) for a prospective biosimilar of denosumab (Prolia and Xgeva; Amgen). The product is intended for addressing a wide range of conditions, such as osteoporosis in postmenopausal women and in men with an elevated fracture risk, alongside numerous other medical conditions.

In July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd. launched Edirol (eldecalcitol) in China after receiving approval from the China National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative created by Chugai.

Treatment Types Covered:

  • Bisphosphonates
  • Hormone Replacement Therapy (HRT)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Monoclonal Antibodies
  • Calcium and Vitamin D Supplements
  • Anabolic Agents
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Transdermal
  • Nasal

Drug Delivery Systems Covered:

  • Conventional Formulations
  • Long-Acting Formulations

Patient Demographics Covered:

  • Postmenopausal Women
  • Elderly Population

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Postmenopausal Osteoporosis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Bisphosphonates
  • 5.3 Hormone Replacement Therapy (HRT)
  • 5.4 Selective Estrogen Receptor Modulators (SERMs)
  • 5.5 Monoclonal Antibodies
  • 5.6 Calcium and Vitamin D Supplements
  • 5.7 Anabolic Agents
  • 5.8 Other Treatment Types

6 Global Postmenopausal Osteoporosis Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Parenteral
    • 6.3.1 Intravenous (IV)
    • 6.3.2 Intramuscular
    • 6.3.3 Subcutaneous
  • 6.4 Transdermal
  • 6.5 Nasal

7 Global Postmenopausal Osteoporosis Treatment Market, By Drug Delivery System

  • 7.1 Introduction
  • 7.2 Conventional Formulations
  • 7.3 Long-Acting Formulations

8 Global Postmenopausal Osteoporosis Treatment Market, By Patient Demographics

  • 8.1 Introduction
  • 8.2 Postmenopausal Women
  • 8.3 Elderly Population

9 Global Postmenopausal Osteoporosis Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Postmenopausal Osteoporosis Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Company (Allergan Pharmaceuticals International Ltd.)
  • 12.2 Sun Pharmaceutical Industries Ltd.
  • 12.3 Amgen Inc.
  • 12.4 BiologicsMD
  • 12.5 Chugai Pharma China Co., Ltd. (Roche)
  • 12.6 Clonz Biotech
  • 12.7 Proctor & Gamble Co.
  • 12.8 Eli Lilly and Company
  • 12.9 Enteris BioPharma
  • 12.10 Ligand Pharmaceuticals Incorporated.
  • 12.11 Pfizer Inc.
  • 12.12 Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
  • 12.13 Mylan Inc. (Viatris)
  • 12.14 Oncobiologics, Inc.
  • 12.15 Novartis International AG

List of Tables

  • Table 1 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 3 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Bisphosphonates (2021-2030) ($MN)
  • Table 4 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hormone Replacement Therapy (HRT) (2021-2030) ($MN)
  • Table 5 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2021-2030) ($MN)
  • Table 6 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 7 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Calcium and Vitamin D Supplements (2021-2030) ($MN)
  • Table 8 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Anabolic Agents (2021-2030) ($MN)
  • Table 9 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 10 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 11 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 12 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 13 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intravenous (IV) (2021-2030) ($MN)
  • Table 14 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 15 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 16 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 17 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 18 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Drug Delivery System (2021-2030) ($MN)
  • Table 19 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Conventional Formulations (2021-2030) ($MN)
  • Table 20 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Long-Acting Formulations (2021-2030) ($MN)
  • Table 21 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Patient Demographics (2021-2030) ($MN)
  • Table 22 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Postmenopausal Women (2021-2030) ($MN)
  • Table 23 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Elderly Population (2021-2030) ($MN)
  • Table 24 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 25 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 26 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 27 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.